peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

Year-End Release 2007

28 Feb 2008, 08:00
Regulatory information

Hansa Medical refines biomedical discoveries into candidate drugs and diagnostic analytical methods. The company’s long-term goal is to bring new products to market through collaboration agreements with pharmaceutical and diagnostics companies. Hansa Medical’s lead project, IdeS, is an innovative drug for treatment in conjunction with organ transplantation and autoimmune disease. The company also pursues other development projects, including diagnostics and drugs for sepsis. Hansa Medical has about 600 shareholders and has been listed on First North, part of the OMX Nordic Exchange Stockholm, since October 2007. Kaupting Bank is the certified advisor.This document is a summary of the full Swedish report. For a full account of the company’s operations, refer to the Swedish report.Financial information• Net sales for the Group amounted to SEK 0.0 M• The operating loss for the Group totaled SEK 3.6 M• Loss per share was 1.21• Cash and cash equivalent for the Group amounted to SEK 31.4 M at the end of the periodSignificant events during the period• Preclinical proof-of-concept achieved for lead project.• Successful new share issue and introduction on First. • Clinical Development plan initiated for lead project. Significant events after the close of the period• Acquisition of all assets in Cartela i konkurs AB for a purchase consideration of SEK 3.9M. CEO’s comments – focus on IdeS and alpha-11“For Hansa Medical, 2007 was an eventful year. Following a fully subscribed new share issue and a company’s subsequent introduction on First North, we are now an independent biotechnology company with tangible and goal oriented development projects. On completion of the share issue, we immediately commenced our clinical development plan for IdeS.”“We achieved key development goals primarily relating to our lead projects IdeS and HMD-301 for the diagnosis and prognosis of sepsis. During 2007, Hansa Medical successfully established links with researchers with strong focus on patient benefits, as well as commercially minded employees with medical expertise.” Emanuel Björne, CEO Hansa Medical AB (publ)For further information, please contact:Emanuel Björne, CEOMobile: +46 (0)707-17 54 77E-mail: emanuel.bjorne@hansamedical.comBo Håkansson, Chairman of the BoardMobile: +46 (0)705-98 57 22 E-mail: